Skip to content
10-Q

Quarterly Report

Goldenwell Biotech, Inc. GWLL

0001477932-24-007630

← back to feed
Filed
Nov 26, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 17, 2024 99M sh
Total Liabilities Q3 2024 · Sep 30, 2024 $198.67K
Total Liabilities Q3 2024 · Dec 31, 2023 $143.33K
Total Assets Q3 2024 · Sep 30, 2024 $179.43K
Total Assets Q3 2024 · Dec 31, 2023 $228.06K
Net Income Q3 2024 · Sep 30, 2024 −$103.96K
Net Income Q3 2024 · Dec 31, 2023 −$20.8K
Net Income Q3 2024 · Sep 30, 2023 −$35.41K
Net Income Q3 2024 · Sep 30, 2023 −$96.1K
Revenue Q3 2024 · Sep 30, 2024 $0
Revenue Q3 2024 · Sep 30, 2024 $297
Revenue Q3 2024 · Sep 30, 2023 $382
Revenue Q3 2024 · Sep 30, 2023 $2.08K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$94.08K
Stockholders Equity restated Q3 2024 · Sep 30, 2023 $105.52K
Stockholders Equity Q3 2024 · Jun 30, 2023 $140.93K
Operating Income Q3 2024 · Sep 30, 2023 −$35.41K
Operating Income Q3 2024 · Sep 30, 2023 −$96.1K
Gross Profit Q3 2024 · Sep 30, 2023 $186
Gross Profit Q3 2024 · Sep 30, 2023 $1.04K
Cost Of Revenue Q3 2024 · Sep 30, 2023 $196
Cost Of Revenue Q3 2024 · Sep 30, 2023 $1.05K